Rupert Vessey, Bristol Myers Squibb president of research and early development (BMS)
Bristol Myers hunkers down at the deals table, executing a new I/O play in biotech buyout
A week after Bristol Myers Squibb plunked down $475 million upfront to partner with Dragonfly on an IL-12 program — which fits neatly into the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
